USC.edu
Are You a Patient?

Jin Piao, PhD

Associate Professor of Clinical Population and Public Health Sciences

Image of Jin Piao, PhD
Is this your profile? Click to edit
Phone +1 626 241 1572
Email [email protected]
CTSI Profile

Overview

Dr. Jin Piao is an Associate Professor from the Division of Biostatistics, Department of Population and Public Health Sciences, the University of Southern California. She has been working on the development of methodological approaches that have direct impacts on biomedical applications. Her research interest lies in the areas including clinical trial design and analysis, survival analysis, semiparametric statistical models, and meta-analysis. In addition to statistical methodological research, she has been actively collaborated with physicians and biologists in pediatric solid tumors areas and supported several phases I, II, or III solid tumors clinical trials at Children’s Oncology Group.

Education and Training

  • The University of Texas Health Science Center at Houston — Doctor of Philosophy (Ph.D.) — 08/2017 — Biostatistics
  • University of Toledo — Master's degree — 05/2012 — Mathematics
  • Tongji University — Bachelor of Science (BS) — 08/2010 — Statistics

Research Keywords

  • Biostatistics
  • Clinical Trials
  • Survival Analysis
  • Meta-Analysis

Publications

  • Semiparametric isotonic regression modelling and estimation for group testing data. Can J Stat. 2021 Sep; 49(3):659-677.. View in PubMed
  • A single-arm study of systemic and sub-Tenon chemotherapy for Groups C and D intraocular retinoblastoma: A Children’s Oncology Group study (ARET 0231). Pediatr Blood Cancer. 2020 09; 67(9):e28502.. View in PubMed
  • The importance of age as prognostic factor for the outcome of patients with hepatoblastoma: Analysis from the Children’s Hepatic tumors International Collaboration (CHIC) database. Pediatr Blood Cancer. 2020 08; 67(8):e28350.. View in PubMed
  • Trial Design Challenges and Approaches for Precision Oncology in Rare Tumors: Experiences of the Children’s Oncology Group. JCO Precis Oncol. 2019; 3.. View in PubMed
  • Study of Unilateral Retinoblastoma With and Without Histopathologic High-Risk Features and the Role of Adjuvant Chemotherapy: A Children’s Oncology Group Study. J Clin Oncol. 2019 11 01; 37(31):2883-2891.. View in PubMed
  • Response adaptive randomization procedures in seamless phase II/III clinical trials. J Biopharm Stat. 2020; 30(1):3-17.. View in PubMed
  • Prognostic model for patient survival in primary anorectal mucosal melanoma: stage at presentation determines relevance of histopathologic features. Mod Pathol. 2020 03; 33(3):496-513.. View in PubMed
  • Evaluation of the diagnostic biopsy approach for children with hepatoblastoma: A report from the children’s oncology group AHEP 0731 liver tumor committee. J Pediatr Surg. 2020 Apr; 55(4):655-659.. View in PubMed
  • Semiparametric Model for Bivariate Survival Data Subject to Biased Sampling. J R Stat Soc Series B Stat Methodol. 2019 Apr; 81(2):409-429.. View in PubMed
  • Prognosis of patients with intermediate risk IPSS-R myelodysplastic syndrome indicates variable outcomes and need for models beyond IPSS-R. Am J Hematol. 2018 10; 93(10):1245-1253.. View in PubMed

Similar People